YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...
Nasdaq

Oruka Therapeutics Announces Accelerated Clinical Timelines and Strong Financial Position for Psoriasis Programs

Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...
Contract Pharma

Aragen Launches CHOMax Platform to Accelerate Path from DNA to Clinical Supply

Aragen's new cell line development and early manufacturing platform, CHOMax, can cut timelines to approximately 10 months.
Hosted on MSN

Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform

CEO Dwight H. Egan reported continued progress on the Co-DX PCR point-of-care platform, stating, "We remain on track to initiate clinical evaluations for all tests in our pipeline during 2025." Egan ...

Avance Clinical to Showcase New Early Phase Center of Excellence at Biotech Showcase 2026

Designed specifically for emerging biotechs, the Early Phase Center of Excellence brings together Avance Clinical’s scientific, regulatory, and operational experts to streamline first-in-human and ...

VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for ...

Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting ...
FierceBiotech

Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

As advancements in medical science progress, clinical research and development (R&D) are subject to more sophisticated and complex study designs and protocols that require precise global coordination ...

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...

MapLight Therapeutics stock rises after accelerating clinical trial timelines

The biopharmaceutical company now anticipates topline data from its ZEPHYR trial for schizophrenia treatment ML-007C-MA in the third quarter of 2026. The study, which will enroll 300 hospitalized ...
pharmaphorum

FDA’s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy

In November 2025, the UK government introduced the national "Government Strategy and Roadmap" for phasing out animal testing.[1] The US Food and Drug Administration (FDA) has also issued a roadmap and ...